Innovation: Intelligent bacteria demonstrate high efficacy in the treatment of widespread disease irritable bowel syndrome with typical symptoms of recurrent diarrhoea, abdominal pain, bloating and constipation

New therapy with unique bacterial strain B. bifidum HI-MIMBb75 promises help for approximately 80 million Europeans suffering from irritable bowel syndrome1 World's largest clinical OTC irritable bowel syndrome trial investigating the efficacy of this particular strain published in the renowned medical journal The Lancet Gastroenterology & Hepatology2 Results show significant efficacy for all predominant irritable bowel syndrome symptoms and all subtypes while simultaneously improving patients’ quality of life2 (Gräfelfing/Munich, Germany) The world's largest OTC irritable bowel syndrome (IBS) trial comes up with remarkable results, which were recently published in the renowned medical journal The Lancet Gastroenterology & Hepatology. For the first time, leading German scientists around Prof. Dr. Peter Layer (Israelitic Hospital Hamburg) were able to prove the significant efficacy of a heat-inactivated bacterial strain on patients with IBS. Trial results show that B. bifidum HI-MIMBb75

Best management of irritable bowel syndrome

Global Research Trends and Hot Spots in the Overlapping Fields of Functional Bowel Disorders and the Intestinal Microbiota: A Scientometric Analysis

Clinical Trials and Studies - IFFGD

Full article: Dynamic changes of intestinal flora in patients with irritable bowel syndrome combined with anxiety and depression after oral administration of enterobacteria capsules

Microorganisms, Free Full-Text

Electroceuticals in the Gastrointestinal Tract: Trends in Pharmacological Sciences

Irritable bowel syndrome - Wikipedia

Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice - Paul Moayyedi, Fermín Mearin, Fernando Azpiroz, Viola Andresen, Giovanni Barbara, Maura Corsetti, Anton Emmanuel, A Pali S Hungin, Peter

Irritable Bowel Syndrome

A Clostridia-rich microbiota contributes to increased excretion of bile acids in diarrhea-predominant irritable bowel syndrome

Mucosal Biofilms Are an Endoscopic Feature of Irritable Bowel Syndrome and Ulcerative Colitis. - Abstract - Europe PMC

Gastroenterology and Endoscopy News Special Edition - October 2021 by McMahon Group - Issuu

JCM, Free Full-Text

Frontiers Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea